Premium
Effect of ethnicity on first trimester biomarkers for combined trisomy 21 screening: results from a multicenter study in six Asian countries
Author(s) -
Manotaya Saknan,
Zitzler Juergen,
Li Xiaotian,
Wibowo Noroyono,
Pham Thi Mai,
Kang Myung Seo,
Lee ChienNan
Publication year - 2015
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.4602
Subject(s) - trisomy , down syndrome , pregnancy associated plasma protein a , pregnancy , medicine , second trimester , first trimester , population , ethnic group , obstetrics , demography , gynecology , fetus , biology , environmental health , genetics , psychiatry , sociology , anthropology
Objective To assess differences between first trimester trisomy 21 screening markers free beta chain of the human chorionic gonadotrophin ( β hCG) and pregnancy‐associated plasma protein A (PAPP‐A) in pregnant women of six different Asian countries (China, Indonesia, Korea, Taiwan, Thailand, and Vietnam) and compare serum levels with those in women of European countries. Methods Median and multiple of median (MoM) values of free βhCG and PAPP‐A were determined in more than 3000 pregnant women from the Asian countries during their first trimester of pregnancy. Differences in MoM values between a European reference group from a previous multicenter evaluation and the Asian population were evaluated. Two different types of population correction factors for T21 risk estimation were assessed. Results An at least 10% difference of median MoMs between European and Asian PAPP‐A values was found to be statistically significant ( p < 0.0001). The specificity of the screening did not show a big difference in individual countries, when using the country‐specific correction factor compared with the overall Asian correction factor (<1.4%). Conclusions The use of a correction factor is recommended based on the differences in European and Asian MoM values. Developing country‐specific medians in larger study populations can help identify clinical relevant differences and give the opportunity to explore a more accurate risk calculation. © 2015 John Wiley & Sons, Ltd.